Ignite Creation Date:
2024-05-06 @ 9:56 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03116529
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-09-13
First Post:
2017-04-12
Brief Title:
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Soft Tissue Sarcoma |
Keywords:
| Name | View |
|---|---|
| Neoadjuvant | View |
| Soft Tissue Sarcoma | View |
| Immunotherapy | View |
| Checkpoint Inhibitor | View |
| PD-1 Programmed Cell Death Protein 1 | View |
| PD-L1 Programmed Death Ligand 1 | View |
| CTLA-4 Cytotoxic T-Lymphocyte-Associated Protein 4 | View |
| Radiotherapy | View |
| Durvalumab | View |
| Tremelimumab | View |
| Surgery | View |
| Radiation | View |
| Combined | View |
| Preoperative | View |